Aerie Pharmaceuticals says that a combo glaucoma drug adding its own treatment to the best-selling standard in the field topped the blockbuster solo therapy in a Phase IIb trial. The results set the stage for a confirmatory Phase III trial, sending its share price soaring more than 40% on Wednesday morning.

…read more

Source: Aerie shares soar as glaucoma combo succeeds in PhIIb eye study


0 No comments